Anders Hove has been with Venrock since 2004. In 2008, Anders founded Venrock Healthcare Capital Partners, Venrock’s public funds focused on small capitalization biotech companies and late-stage private companies. His investment activities span biotechnology companies at all stages, from early stage seed to public investments. He currently serves on the Board of Directors of Anacor Pharmaceuticals (NASDAQ: ANAC) and Edge Therapeutics (NASDAQ: EDGE) as well as several private company Boards, including Intuity Medical and Impopharma. Recently he led Venrock’s private investments into Ascendis, Coherus, Edge Therapeutics, Tesaro and Zafgen, Previous investments where Anders served as a Board member include Adnexus Therapeutics (acquired by Bristol-Myers Squibb), Eyetech Pharmaceuticals (acquired by OSI Pharmaceuticals), PEAK Surgical (acquired by Medtronic), and The Medicines Company (NASDAQ: MDCO). In 2011, Anders was named to Forbes’ Midas List, which ranks the top venture capitalists in life sciences and technology.
Prior to Venrock, Anders held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy, and later as the portfolio manager of BB Biotech and CEO of Bellevue Asset Management. At Bellevue, Anders had responsibility for managing BB Biotech, an investment company with several billion dollar invested in public and private biotech companies. While at BB Biotech, Anders led numerous public and private investments and BB Biotech was the largest shareholder in companies such as Alexion (NASDAQ: ALXN), Medimmune (acquired by Astra Zeneca) and Aviron (acquired by Medimmune).
Anders earned his M.Sc. in Biotechnology Engineering from the Technical University of Denmark, his M.D. at the University of Copenhagen and an M.B.A. from INSEAD.